Ovid Therapeutics to Participate in Citi’s 10th Annual Biotech Conference

NEW YORK--()--Ovid Therapeutics Inc. (Ovid), a privately held biopharmaceutical company focused on developing therapies for rare and orphan diseases of the brain, announced today that Dr. Yaron Werber, Ovid’s Chief Financial Officer, will participate on a panel, titled “Rare Diseases – Behind Enzyme Replacement Therapy,” during Citi’s 10th Annual Biotech Conference, taking place at the Mandarin Oriental New York, September 9-10, 2015. The panel will convene on Thursday, September 10, at 9am Eastern Time.

About Ovid Therapeutics Inc.

Ovid Therapeutics Inc. is a privately held, New York-based, biopharmaceutical company committed to transforming the lives of patients with rare and orphan diseases of the brain. Ovid focuses on patients and their unmet medical needs. Using the significant operational, product development and business development experience of its management team, Ovid aims to become a leading neurology company, with multiple products and a rich pipeline, coupled with compelling research and development.

For more information on Ovid, please visit http://www.ovidrx.com.

Contacts

Burns McClellan, on behalf of Ovid Therapeutics
Justin Jackson, 212-213-0006, ext. 327
jjackson@burnsmc.com

Contacts

Burns McClellan, on behalf of Ovid Therapeutics
Justin Jackson, 212-213-0006, ext. 327
jjackson@burnsmc.com